//
Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Dr. Lori Sokoll

Ph.D.
Interests

immunoassays tumor markers

Titles

Associate Professor of Pathology, Oncology, and Urology

Schools\Degrees

Ph.D., Nutrition Sciences, Tufts University

Clinical Interests

Clinical chemistry, tumor markers, prostate and breast cancers

Research Summary

Despite the success of PSA as a tumor marker for the early detection and monitoring of disease in prostate cancer and its standing as the most effective tumor marker in the field of oncology, both clinical and analytical limitations of PSA still remain. Research in the laboratory has focused on approaches to improve the clinical utility of PSA for the early detection of prostate cancer, as well as for the management of patients with the disease and on the development and evaluation of new tumor markers assays for prostate cancer. Analytical and clinical studies on the molecular forms of PSA, including free PSA and cPSA, human kallikrein 2 (hK2), and other biomarkers, have shown that the clinical utility of PSA can be improved with these markers and that there is a need for new, novel biomarkers for prostate and other cancers.

Journal Citations

Borowitz, M., Westra, W.H., Illei, P.B., Cooley, L.D., Kant, J.A., Sokoll, L.J., Chan, D.W., and Sanfilippo, F. (2008). Pathology and Laboratory Medicine. In: Clinical Oncology, eds. Abeloff, Armitage, Kastan, and Niederhuberl, Philadelphia: W.B. Saunders. In Press.

Cameron, S.J., Gerhardt, G., Engelstad, M., Young, M.A., Norris, E.J., and Sokoll, L.J. (2008). Interference in clinical chemistry assays by the hemoglobin-based oxygen carrier, Hemospan((R)). Clin Biochem.

Diehl, F., Schmidt, K., Choti, M.A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S.A., Kinzler, K.W., Vogelstein, B., and Diaz, L.A., Jr. (2008). Circulating mutant DNA to assess tumor dynamics. Nature medicine 14, 985-990.

Duffield, A.S., Jarrar, P., Shum, C., Ahuja, N., Yeo, C.J., and Sokoll, L.J. (2008). Retroperitoneal masses with associated human chorionic gonadotropin production: Report of two cases. Clin Chim Acta 395, 166-169.

Freedland, S. J., Sokoll, L. J., Platz, E. A., Mangold, L. A., Bruzek, D. J., Mohr, P., Yiu, S. K. & Partin, A. W. (2005). Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 174, 1266-70.

Fujita, K., Ewing, C.M., Sokoll, L.J., Elliott, D.J., Cunningham, M., De Marzo, A.M., Isaacs, W.B., and Pavlovich, C.P. (2008). Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate 68, 872-882.

Leman, E. S., G. W. Cannon, B. J. Trock, L. J. Sokoll, D. W. Chan, L. Mangold, A. W. Partin, and R. H. Getzenberg. 2007. EPCA-2: a highly specific serum marker for prostate cancer. Urology 69:714-20.

Leman, E.S., Schoen, R.E., Magheli, A., Sokoll, L.J., Chan, D.W., and Getzenberg, R.H. (2008). Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res 14, 1349-1354.

Li, Y., Sokoll, L.J., Rush, J., Meany, D.L., Zou, N., Chan, D.W., and Zhang H. (2009). Targeted Detection of Prostate Tumor Proteins in Serum Using Heavy-Isotope-Labeled-Peptide Standards and MALDI-TOF/TOF. Proteomics In Press.

Loeb, S., Chan, D.W., Sokoll, L., Kan, D., Maggiore, J., Mikolajczyk, S.D., Mondo, D.M., Griffin, C.R., and Catalona, W.J. (2008). Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol 180, 1959-1962; discussion 1962-1953.

McLerran, D., Grizzle, W.E., Feng, Z., Thompson, I.M., Bigbee, W.L., Cazares, L.H., Chan, D.W., Dahlgren, J., Diaz, J., Kagan, J., Lin, D.W., Malik, G., Oelschlager, D., Partin, A., Randolph, T.W., Sokoll, L., Srivastava, S., Srivastava, S., Thornquist, M., Troyer, D., Wright, G.L., Zhang, Z., Zhu, L., and Semmes, O.J. (2008). SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 54, 53-60.

McLerran, D., W. E. Grizzle, Z. Feng, I. M. Thompson, W. L. Bigbee, L. H. Cazares, D. W. Chan, J. Dahlgren, J. Diaz, J. Kagan, D. W. Lin, G. Malik, D. Oelschlager, A. Partin, T. W. Randolph, L. Sokoll, S. Srivastava, S. Srivastava, M. Thornquist, D. Troyer, G. L. Wright, Z. Zhang, L. Zhu, and O. J. Semmes. 2008. SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. Clin Chem 54:53-60.

Meany, D.L., Zhang, Z., Sokoll, L.J., Zhang, H., and Chan, D.W. (2008). Glycoproteomics for Prostate Cancer Detection: Changes in Serum PSA Glycosylation Patterns. J Proteome Res 8, 613-319.

Parsons, J. K., A. W. Partin, B. Trock, D. J. Bruzek, C. Cheli, and L. J. Sokoll. 2007. Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy. BJU Int 99:758-61.

Parsons, J. K., Sokoll, L. J., Trock, B. J., Bruzek, D. J., Cheli, C. D. & Partin, A. W. (2005). Validity of complexed prostate specific antigen (cPSA) for the diagnosis of biochemical recurrence after radical retropubic prostatectomy. In Journal of Urology, pp. Suppl:259.

Rosenzweig, C.N., Zhang, Z., Sun, X., Sokoll, L.J., Osborne, K., Partin, A.W., and Chan, D.W. (2009). Predicting Prostate Cancer Biochemical Recurrence Using a Panel of Serum Proteomic Biomarkers. J Urol. 181, 1407-1414.

Sokoll, L. J., W. Ellis, P. Lange, J. Noteboom, D. J. Elliott, I. L. Deras, A. Blase, S. Koo, M. Sarno, H. Rittenhouse, J. Groskopf, and R. L. Vessella. 2007. A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta.

Sokoll, L.J., Ellis, W., Lange, P., Noteboom, J., Elliott, D.J., Deras, I.L., Blase, A., Koo, S., Sarno, M., Rittenhouse, H., Groskopf, J., and Vessella, R.L. (2008). A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 389, 1-6.

Sokoll, L.J., Wang, Y., Feng, Z., Kagan, J., Partin, A.W., Sanda, M.G., Thompson, I.M., and Chan, D.W. (2008). [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 180, 539-543; discussion 543.

Song, J., Patel, M., Rosenzweig, C. N., Chan-Li, Y., Sokoll, L. J., Fung, E. T., Choi-Miura, N. H., Goggins, M., Chan, D. W. & Zhang, Z. (2006). Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem 52, 1045-53.

Sturgeon, C.M., Duffy, M.J., Stenman, U.H., Lilja, H., Brunner, N., Chan, D.W., Babaian, R., Bast, R.C., Jr., Dowell, B., Esteva, F.J., Haglund, C., Harbeck, N., Hayes, D.F., Holten-Andersen, M., Klee, G.G., Lamerz, R., Looijenga, L.H., Molina, R., Nielsen, H.J., Rittenhouse, H., Semjonow, A., Shih Ie, M., Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B.R., and Diamandis, E.P. (2008). National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54, e11-79.

Sutcliffe, S., Zenilman, J. M., Ghanem, K. G., Jadack, R. A., Sokoll, L. J., Elliott, D. J., Nelson, W. G., DeMarzo, A. M., Cole, S. R., Isaacs, W. B. & Platz, E. A. (2006). Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol 175, 1937-42.

Tobian, A.A., Sokoll, L.J., Tisch, D.J., Ness, P.M., and Shan, H. (2008). N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload. Transfusion 48, 1143-1150.

Bieglmayer, C., Chan, D. W., Sokoll, L. J., Imdahl, R., Kobayashi, M., Yamada, E., et al. 2004. Multicentre performance evaluation of the E170 module for modular analytics. Clin. Chem. Lab Med. 42:1186-1202.

Khan, M. A., Sokoll, L. J., Chan, D. W., Mangold, L. A., Mohr, P., Mikolajczyk, S. D., et al. 2004. Clinical utility of proPSA and "benign" PSA when percent-free PSA is less than 15 percent. Urology. 64:1160-1164.

Koopman, J., Buckhaults, P., Brown, D. A., Zahurek, M. L., Sato, N., Fukushima, N., et al. 2004. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin. Cancer Res. 10:2386-2392.

Wang, Y. Y., Kuhajda, F. P., Li, J., Finch, T. T., Cheng, P., Koh, C., et al. 2004. Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer. J. Exp. Ther. Oncol. 4:101-110.

Zhang, Z., Bast, R. C., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., et al. 2004. Three biomarkers identified from serum proteomic analysis for the detection of early state ovarian cancer. Cancer Res. 64:5882-5890.

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.